European Medicines Agency to grant ReMedys with an Orphan Medicinal Product Designation

The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency, that is responsible for reviewing applications from people or companies seeking 'orphan-medicinal-product designation', issued on the12 of February 2015 a positive opinion on the ReMedys application for orphan drug designation for a generic drug that ReMedys is repositoning as a therapeutic option for the Amyotrophic Lateral Sclerosis.